FDA Clearance Tracker · P970003-S166
VNS THERAPY SYSTEM
Last checked: Nov 20, 2026Latest source record: May 9, 2014 (this decision)Source: openFDAMethods & limitations
Decided
May 9, 2014
Approved
Time to decision
189 days
Received Nov 1, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P970003-S166
- Device name
- VNS THERAPY SYSTEM
- Applicant
- LivaNova USA, Inc.
- Applicant location
- Houston, TX
- Received
- Nov 1, 2013
- Decided
- May 9, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P970003
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR LABELING THAT DESCRIBES THE CONDITIONS UNDER WHICH MAGNETIC RESONANCE IMAGING (MRI) CAN BE USED WHEN RESIDUAL VNS LEADS OR LEAD FRAGMENTS (ABANDONED LEADS) REMAIN IN THE BODY.
Source documents
Other decisions for LivaNova USA, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250013 · Decided Mar 18, 2026 · 327 days after receipt
Device type: Stimulator, hypoglossal nerve, implanted, apnea (MNQ) · Anesthesiology & Respiratory
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.